Alaska Permanent Fund Corp Sells 45,855 Shares of Bristol-Myers Squibb (NYSE:BMY)

Alaska Permanent Fund Corp decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 15.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 249,206 shares of the biopharmaceutical company’s stock after selling 45,855 shares during the quarter. Alaska Permanent Fund Corp’s holdings in Bristol-Myers Squibb were worth $12,787,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. RFG Advisory LLC raised its position in shares of Bristol-Myers Squibb by 13.7% in the 3rd quarter. RFG Advisory LLC now owns 16,952 shares of the biopharmaceutical company’s stock worth $984,000 after purchasing an additional 2,046 shares during the last quarter. Onyx Bridge Wealth Group LLC increased its holdings in Bristol-Myers Squibb by 25.3% in the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 7,226 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 1,457 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its holdings in Bristol-Myers Squibb by 58.3% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,967 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 1,830 shares in the last quarter. BTC Capital Management Inc. increased its holdings in Bristol-Myers Squibb by 7.9% in the 3rd quarter. BTC Capital Management Inc. now owns 92,514 shares of the biopharmaceutical company’s stock worth $5,370,000 after buying an additional 6,746 shares in the last quarter. Finally, Advisors Management Group Inc. ADV grew its stake in shares of Bristol-Myers Squibb by 19.9% during the 3rd quarter. Advisors Management Group Inc. ADV now owns 7,717 shares of the biopharmaceutical company’s stock valued at $448,000 after purchasing an additional 1,281 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded down $2.55 during midday trading on Thursday, hitting $46.31. 3,224,143 shares of the company were exchanged, compared to its average volume of 15,351,132. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. Bristol-Myers Squibb has a fifty-two week low of $46.13 and a fifty-two week high of $69.74. The business has a fifty day simple moving average of $51.22 and a two-hundred day simple moving average of $51.31. The firm has a market capitalization of $93.86 billion, a PE ratio of 12.33, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.50) by $0.10. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same period last year, the company earned $2.05 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.18%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.